ORX Orexo AB

Number of Shares and Votes in Orexo

UPPSALA, Sweden--(BUSINESS WIRE)--

The number of shares and votes in Orexo AB (STO:ORX) has changed as a result of the exercise of warrants in connection with the company’s incentive programs.

Today, the last trading day of the month, there are in total 34,666,107 shares - whereof 34,531,107 are ordinary shares and 135,000 class C shares - and 34,544,607 votes in the company.

About Orexo

Orexo is a specialty pharmaceutical company commercializing its proprietary product Zubsolv® for treatment of opioid dependence in the US. Zubsolv is an advanced formulation of buprenorphine and naloxone using Orexo’s unique knowledge and expertise in sublingual drug delivery. R&D is focusing on reformulation of known substances to new improved products that meet great unmet medical needs by using its patented proprietary technologies. Orexo’s share is listed on Nasdaq Stockholm Exchange Mid Cap (STO: ORX) and is available as ADRs on OTCQX (ORXOY) in the US. Orexo’s global headquarters and R&D are based in Uppsala, Sweden.

For more information about Orexo, please visit www.orexo.com or follow us on Twitter or LinkedIn. For further information about Zubsolv in the US, please visit www.zubsolv.com.

The information was submitted for publication at 6:00pm CET, September 30, 2016

This information was brought to you by Cision http://news.cision.com

EN
30/09/2016

Underlying

ORXOrexo AB

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Orexo AB

Free Trial
ORX OREXO AB

Orexo AB: 1 director

A director at Orexo AB bought 17,000 shares at 1.885EUR and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...

06/13/25 June 13, 2025 1 EN
Glenn Kringhaug
  • Glenn Kringhaug
ORX OREXO AB

Orexo - Q3 miss, but no worries

Higher sales and marketing spend resulted in Q3 miss The operational momentum is good Low-risk credit at a decent spread

11/03/22 November 3, 2022 1 EN
Glenn Kringhaug
  • Glenn Kringhaug
ORX OREXO AB

Orexo - Progress is being made

Q2 was fairly in line Progress being made for reimbursements of DTs We remain comfortable with the credit

08/01/22 August 1, 2022 1 EN
Glenn Kringhaug
  • Glenn Kringhaug
ORX OREXO AB

Orexo - A strong report across the board

EBITDA excl. R&D was ~43% above our estimate Finally some light in the tunnel for Digital Therapeutics Attractive and low-risk credit offering decent yield

04/28/22 April 28, 2022 1 EN
Glenn Kringhaug
  • Glenn Kringhaug
ORX OREXO AB

Orexo - A lot is going on, but it will take time

Credit neutral Q4 Many projects, but limited financial benefit yet We remain positive to the credit

01/27/22 January 27, 2022 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch